→ PTOBF

Attorney Docket No.:

RTS-0350

Inventors:

Freier and Roach

Serial No.:

10/017,621

Filing Date:

December 7, 2001

Page 2

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

Claim 1 (currently amended): A modified compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PCTAIRE protein kinase 1 (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding PCTAIRE protein kinase 1 and inhibits the expression of PCTAIRE protein kinase 1.

Claim 2 (currently amended): The compound of claim 1 wherein said compound which is an a modified antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothicate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

→ PTOBF

RTS-0350 Attorney Docket No.:

Freier and Roach Inventors:

10/017,621 Serial No.:

December 7, 2001 Filing Date:

Page 3

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the one modified antisense oligonucleotide comprises least at nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

The compound of claim 2 wherein the Claim 10 (original): antisense oliqonucleotide is a chimeric oliqonucleotide.

Claim 11 (original): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding PCTAIRE protein kinase 1.

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Attorney Docket No.:

RTS-0350

Inventors:

Freier and Roach

Serial No.:

10/017,621

Filing Date:

December 7, 2001

Page 4

Claim 15 (withdrawn): A method of inhibiting the expression of PCTATRE protein kinase 1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of PCTAIRE protein kinase 1 is inhibited.

Claim 16 (withdrawn): A method of treating an animal having a disease or condition associated with PCTAIRE protein kinase 1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of PCTAIRE protein kinase 1 is inhibited.

Claim 17 (withdrawn): The method of claim 16 wherein the disease or condition is a hyperproliferative disease.

Claim 18 (withdrawn): The method of claim 16 wherein the disease or condition is a neurological disease.

Claim 19 (withdrawn): The compound of claim 1 targeted to a nucleic acid molecule encoding PCTAIRE protein kinase 1, wherein said compound specifically hybridizes with and differentially inhibits the expression of one of the variants of PCTAIRE protein kinase 1 relative to the remaining variants of PCTAIRE protein kinase 1.

Claim 20 (withdrawn): The compound of claim 19 targeted to a nucleic acid molecule encoding PCTAIRE protein kinase 1, wherein said compound hybridizes with and specifically inhibits the expression of a variant of PCTAIRE protein kinase 1, wherein said Attorney Docket No.: RTS-0350

Inventors:

Freier and Roach

Serial No.:

10/017,621

Filing Date:

December 7, 2001

Page 5

variant is selected from the group consisting of PCTAIRE 1 and PCTAIRE-1B.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defeats in the images include but are not limited to the items checked:

Defects in the images include but are not immed to the nems encered.
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
RAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.